Compare MGIC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIC | PCRX |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.3M | 1.0B |
| IPO Year | 1991 | 2011 |
| Metric | MGIC | PCRX |
|---|---|---|
| Price | $27.44 | $23.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $18.00 | ★ $32.86 |
| AVG Volume (30 Days) | 37.3K | ★ 882.7K |
| Earning Date | 11-18-2025 | 02-26-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 16.15 | N/A |
| EPS | ★ 0.81 | 0.47 |
| Revenue | $603,216,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $12.87 | $6.24 |
| Revenue Next Year | $6.23 | $9.53 |
| P/E Ratio | ★ $33.10 | $55.21 |
| Revenue Growth | ★ 12.65 | 3.14 |
| 52 Week Low | $11.36 | $18.18 |
| 52 Week High | $27.44 | $27.64 |
| Indicator | MGIC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 40.40 |
| Support Level | $26.77 | $24.20 |
| Resistance Level | $27.31 | $26.48 |
| Average True Range (ATR) | 0.55 | 1.06 |
| MACD | -0.05 | -0.23 |
| Stochastic Oscillator | 98.71 | 29.39 |
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.